Contraceptives with novel benefits

Bibliography

• Law ML, Kao FT, Wei Q, ?>The progesterone receptor gene maps to human chromosome band 11q13, the site of the mammary oncogene int-2. Proc Natl Acad Sci USA 1987;84:2877-81
   PubMed Web of Science ®Google Scholar
• Gadkar-Sable S, Shah C, Rosario G, Progesterone receptors: various forms and functions in reproductive tissues. Front Biosci 2005;10:2118-30
   PubMed Web of Science ®Google Scholar
• Kastner P, Krust A, Turcotte B, Two distinct estrogen-regulated promoters generate transcripts encoding the two functionally different human progesterone receptor forms A and B. EMBO J 1990;9:1603-14
   PubMed Web of Science ®Google Scholar
• Tora L, Gronemeyer H, Turcotte B, The N-terminal region of the chicken progesterone receptor specifies target gene activation. Nature 1988;333:185-8
   PubMed Web of Science ®Google Scholar
• Giangrande PH, McDonnell DP. The A and B isoforms of the human progesterone receptor: two functionally different transcription factors encoded by a single gene. Recent Prog Horm Res 1999;54:291-313; discussion 313-294
   PubMedGoogle Scholar
• Mulac-Jericevic B, Mullinax RA, DeMayo FJ, Subgroup of reproductive functions of progesterone mediated by progesterone receptor-B isoform. Science 2000;289:1751-4
   PubMed Web of Science ®Google Scholar
• Mulac-Jericevic B, Lydon JP, DeMayo FJ, Conneely OM. Defective mammary gland morphogenesis in mice lacking the progesterone receptor B isoform. Proc Natl Acad Sci USA 2003;100:9744-9
   PubMed Web of Science ®Google Scholar
• Schumacher M, Guennoun R, Robert F, Local synthesis and dual actions of progesterone in the nervous system: neuroprotection and myelination. Growth Horm IGF Res 2004;14Suppl(A):S18-33
   PubMedGoogle Scholar
• Attardi BJ, Burgenson J, Hild SA, Reel JR. In vitro antiprogestational/antiglucocorticoid activity and progestin and glucocorticoid receptor binding of the putative metabolites and synthetic derivatives of CDB-2914, CDB-4124, and mifepristone. J Steroid Biochem Mol Biol 2004;88:277-88
   PubMed Web of Science ®Google Scholar
• Schindler AE, Campagnoli C, Druckmann R, Classification and pharmacology of progestins. Maturitas 2008;61:171-80
   PubMed Web of Science ®Google Scholar
• Sitruk-Ware R. New progestogens: a review of their effects in perimenopausal and postmenopausal women. Drugs Aging 2004;21:865-83
   PubMed Web of Science ®Google Scholar
• Fuhrmann U, Krattenmacher R, Slater EP, Fritzemeier KH. The novel progestin drospirenone and its natural counterpart progesterone: biochemical profile and antiandrogenic potential. Contraception 1996;54:243-51
   PubMed Web of Science ®Google Scholar
• Oelkers W. Drospirenone, a progestogen with antimineralocorticoid properties: a short review. Mol Cell Endocrinol 2004;217:255-61
   PubMed Web of Science ®Google Scholar
• Schindler AE. Differential effects of progestins on hemostasis. Maturitas 2003;46(Suppl 1):S31-7
   PubMed Web of Science ®Google Scholar
• Muhn P, Fuhrmann U, Fritzemeier KH, Drospirenone: a novel progestogen with antimineralocorticoid and antiandrogenic activity. Ann N Y Acad Sci 1995;761:311-35
   PubMed Web of Science ®Google Scholar
• Oelkers WK. Effects of estrogens and progestogens on the renin-aldosterone system and blood pressure. Steroids 1996;61:166-71
   PubMed Web of Science ®Google Scholar
• Elger W, Beier S, Pollow K, Conception and pharmacodynamic profile of drospirenone. Steroids 2003;68:891-905
   PubMed Web of Science ®Google Scholar
• Krattenmacher R. Drospirenone: pharmacology and pharmacokinetics of a unique progestogen. Contraception 2000;62:29-38
   PubMed Web of Science ®Google Scholar
• Johansson ED, Sitruk-Ware R. New delivery systems in contraception: vaginal rings. Am J Obstet Gynecol 2004;190:S54-9
   PubMed Web of Science ®Google Scholar
• Keam SJ, Wagstaff AJ. Ethinylestradiol/drospirenone: a review of its use as an oral contraceptive. Treat Endocrinol 2003;2:49-70
   PubMedGoogle Scholar
• Endrikat J, Blode H, Gerlinger C, A pharmacokinetic study with a low-dose oral contraceptive containing 20 microg ethinylestradiol plus 100 microg levonorgestrel. Eur J Contracept Reprod Health Care 2002;7:79-90
   PubMed Web of Science ®Google Scholar
• Machado RB, Pompei Lde M, Giribela AG, Giribela CG. Drospirenone/ethinylestradiol: a review on efficacy and noncontraceptive benefits. Womens Health (Lond Engl) 2011;7:19-30
   PubMedGoogle Scholar
• Maloney JM, Dietze P Jr, Watson D, Treatment of acne using a 3-milligram drospirenone/20-microgram ethinyl estradiol oral contraceptive administered in a 24/4 regimen: a randomized controlled trial. Obstet Gynecol 2008;112:773-81
   PubMed Web of Science ®Google Scholar
• Koltun W, Lucky AW, Thiboutot D, Efficacy and safety of 3 mg drospirenone/20 mcg ethinylestradiol oral contraceptive administered in 24/4 regimen in the treatment of acne vulgaris: a randomized, double-blind, placebo-controlled trial. Contraception 2008;77:249-56
   PubMed Web of Science ®Google Scholar
• van Vloten WA, van Haselen CW, van Zuuren EJ, The effect of 2 combined oral Contraceptives containing either drospirenone or cyproterone acetate on acne and seborrhea. Cutis 2002;69:2-15
   PubMedGoogle Scholar
• Thorneycroft H, Gollnick H, Schellschmidt I. Superiority of a combined contraceptive containing drospirenone to a triphasic preparation containing norgestimate in acne treatment. Cutis 2004;74:123-30
   PubMed Web of Science ®Google Scholar
• Marr J, Niknian M, Shulman LP, Lynen R. Premenstrual dysphoric disorder symptom cluster improvement by cycle with the combined oral contraceptive ethinylestradiol 20 mcg plus drospirenone 3 mg administered in a 24/4 regimen. Contraception 2011;84:81-6
   PubMed Web of Science ®Google Scholar
• Marr J, Heinemann K, Kunz M, Rapkin A. Ethinyl estradiol 20 mug/drospirenone 3 mg 24/4 oral contraceptive for the treatment of functional impairment in women with premenstrual dysphoric disorder. Int J Gynaecol Obstet 2011;113:103-7
   PubMed Web of Science ®Google Scholar
• Foidart JM, Faustmann T. Advances in hormone replacement therapy: weight benefits of drospirenone, a 17alpha-spirolactone-derived progestogen. Gynecol Endocrinol 2007;23:692-9
   PubMed Web of Science ®Google Scholar
• Catherino WH, Jordan VC. Nomegestrol acetate, a clinically useful 19-norprogesterone derivative which lacks estrogenic activity. J Steroid Biochem Mol Biol 1995;55:239-46
   PubMed Web of Science ®Google Scholar
• Lello S. Nomegestrol acetate: clinical pharmacology. Minerva Ginecol 2009;61:459-63
   PubMedGoogle Scholar
• Bullock LP, Bardin CW. Androgenic, synandrogenic, and antiandrogenic actions of progestins. Ann N Y Acad Sci 1977;286:321-30
   PubMed Web of Science ®Google Scholar
• Lello S. Nomegestrol acetate: pharmacology, safety profile and therapeutic efficacy. Drugs 2010;70:541-59
   PubMed Web of Science ®Google Scholar
• Christin-Maitre S, Serfaty D, Chabbert-Buffet N, Comparison of a 24-day and a 21-day pill regimen for the novel combined oral contraceptive, nomegestrol acetate and 17beta-estradiol (NOMAC/E2): a double-blind, randomized study. Hum Reprod 2011;26:1338-47
   PubMed Web of Science ®Google Scholar
• Gaussem P, Alhenc-Gelas M, Thomas JL, Haemostatic effects of a new combined oral contraceptive, nomegestrol acetate/17beta-estradiol, compared with those of levonorgestrel/ethinyl estradiol. A double-blind, randomised study. Thromb Haemost 2011;105:560-7
   PubMed Web of Science ®Google Scholar
• Coutinho EM. One year contraception with a single subdermal implant containing nomegestrol acetate (Uniplant). Contraception 1993;47:97-105
   PubMed Web of Science ®Google Scholar
• Barbosa I, Coutinho E, Hirsch C, Effects of a single contraceptive silastic implant containing nomegestrol acetate on ovarian function and cervical mucus production during 2 years. Fertil Steril 1996;65:724-9
   PubMed Web of Science ®Google Scholar
• Persiani P, Radici E, Lombardi PA, Lombardi PL. Use of nomegestrol acetate in the treatment of menstruation disorders. Our experience in 56 cases. Minerva Ginecol 1997;49:181-5
   PubMedGoogle Scholar
• Fraser DI, Padwick ML, Whitehead MI, The effects of the addition of nomegestrol acetate to post-menopausal oestrogen therapy. Maturitas 1989;11:21-34
   PubMed Web of Science ®Google Scholar
• Kumar N, Koide SS, Tsong Y, Sundaram K. Nestorone: a progestin with a unique pharmacological profile. Steroids 2000;65:629-36
   PubMed Web of Science ®Google Scholar
• Diaz S, Schiappacasse V, Pavez M, Clinical trial with Nestorone subdermal contraceptive implants. Contraception 1995;51:33-8
   PubMed Web of Science ®Google Scholar
• Lahteenmaki PL, Diaz S, Miranda P, Milk and plasma concentrations of the progestin ST-1435 in women treated parenterally with ST-1435. Contraception 1990;42:555-62
   PubMed Web of Science ®Google Scholar
• Fraser IS, Weisberg E, Kumar N, An initial pharmacokinetic study with a Metered Dose Transdermal System for delivery of the progestogen Nestorone as a possible future contraceptive. Contraception 2007;76:432-8
   PubMed Web of Science ®Google Scholar
• Fotherby K. Potency and pharmacokinetics of gestagens. Contraception 1990;41:533-50
   PubMed Web of Science ®Google Scholar
• Noe G, Salvatierra A, Heikinheimo O, Pharmacokinetics and bioavailability of ST 1435 administered by different routes. Contraception 1993;48:548-56
   PubMed Web of Science ®Google Scholar
• Prasad PV, Bashir M, Sitruk-Ware R, Kumar N. Single-dose pharmacokinetics of Nestorone, a potential female-contraceptive. Steroids 2010;75:252-64
   PubMed Web of Science ®Google Scholar
• Sivin I, Mishell DR Jr, Alvarez F, Contraceptive vaginal rings releasing Nestorone and ethinylestradiol: a 1-year dose-finding trial. Contraception 2005;71:122-9
   PubMed Web of Science ®Google Scholar
• Sitruk-Ware R, Small M, Kumar N, Nestorone: clinical applications for contraception and HRT. Steroids 2003;68:907-13
   PubMed Web of Science ®Google Scholar
• Massai MR, Diaz S, Quinteros E, Contraceptive efficacy and clinical performance of Nestorone implants in postpartum women. Contraception 2001;64:369-76
   PubMed Web of Science ®Google Scholar
• Nath A, Sitruk-Ware R. Parenteral administration of progestins for hormonal replacement therapy. Eur J Contracept Reprod Health Care 2009;14:88-96
   PubMed Web of Science ®Google Scholar
• Lenzi E, Pluchino N, Begliuomini S, Central modifications of allopregnanolone and beta-endorphin following subcutaneous administration of Nestorone. J Steroid Biochem Mol Biol 2009;116:15-20
   PubMed Web of Science ®Google Scholar
• Liu L, Zhao L, She H, Clinically relevant progestins regulate neurogenic and neuroprotective responses in vitro and in vivo. Endocrinology 2010;151:5782-94
   PubMed Web of Science ®Google Scholar
• Sitruk-Ware R, Nath A. The use of newer progestins for contraception. Contraception 2010;82:410-17
   PubMed Web of Science ®Google Scholar
• Sitruk-ware R. Neuroprotection and meyelin repair using Nestorone. in WIPO Patent Application. The Population Council, Inc; USA: 2011
   Google Scholar
• Oettel M, Bervoas-Martin S, Elger W, A 19-norprogestin without 17alpha-ethinyl group II: Dienogest from a pharmacokinetic point of view. Drugs Today 1995;31:499-516
   Google Scholar
• Sasagawa S, Shimizu Y, Kami H, Dienogest is a selective progesterone receptor agonist in transactivation analysis with potent oral endometrial activity due to its efficient pharmacokinetic profile. Steroids 2008;73:222-31
   PubMed Web of Science ®Google Scholar
• Foster RH, Wilde MI. Dienogest. Drugs 1998;56:825-33; discussion 834-825
   PubMed Web of Science ®Google Scholar
• Sitruk-Ware R. Pharmacological profile of progestins. Maturitas 2008;61:151-7
   PubMed Web of Science ®Google Scholar
• Teichmann A. Pharmacology of estradiol valerate/dienogest. Climacteric 2003;6(Suppl 2):17-23
   PubMedGoogle Scholar
• Zeun S, Lu M, Uddin A, Pharmacokinetics of an oral contraceptive containing oestradiol valerate and dienogest. Eur J Contracept Reprod Health Care 2009;14:221-32
   PubMed Web of Science ®Google Scholar
• Wiegratz I, Stahlberg S, Manthey T, Effect of extended-cycle regimen with an oral contraceptive containing 30 mcg ethinylestradiol and 2 mg dienogest on bleeding patterns, safety, acceptance and contraceptive efficacy. Contraception 2011;84:133-43
   PubMed Web of Science ®Google Scholar
• Palacios S, Wildt L, Parke S, Efficacy and safety of a novel oral contraceptive based on oestradiol (oestradiol valerate/dienogest): a Phase III trial. Eur J Obstet Gynecol Reprod Biol 2010;149:57-62
   PubMed Web of Science ®Google Scholar
• Klipping C, Duijkers I, Parke S, Hemostatic Effects of a Novel Estradiol-Based Oral Contraceptive: An Open-Label, Randomized, Crossover Study of Estradiol Valerate/Dienogest versus Ethinylestradiol/Levonorgestrel. Drugs R D 11 159-70
   PubMedGoogle Scholar
• Schneider HP. Androgens and antiandrogens. Ann N Y Acad Sci 2003;997:292-306
   PubMed Web of Science ®Google Scholar
• Fraser IS, Romer T, Parke S, Effective treatment of heavy and/or prolonged menstrual bleeding with an oral contraceptive containing estradiol valerate and dienogest: a randomized, double-blind Phase III trial. Hum Reprod 2011;26:2698-708
   PubMed Web of Science ®Google Scholar
• Fraser IS, Parke S, Mellinger U, Effective treatment of heavy and/or prolonged menstrual bleeding without organic cause: pooled analysis of two multinational, randomised, double-blind, placebo-controlled trials of oestradiol valerate and dienogest. Eur J Contracept Reprod Health Care 2011;16:258-69
   PubMed Web of Science ®Google Scholar
• Petraglia F, Hornung D, Seitz C, Reduced pelvic pain in women with endometriosis: efficacy of long-term dienogest treatment. Arch Gynecol Obstet 2011; [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Winneker RC, Bitran D, Zhang Z. The preclinical biology of a new potent and selective progestin: trimegestone. Steroids 2003;68:915-20
   PubMed Web of Science ®Google Scholar
• Sitruk-Ware R, Bossemeyer R, Bouchard P. Preclinical and clinical properties of trimegestone: a potent and selective progestin. Gynecol Endocrinol 2007;23:310-19
   PubMed Web of Science ®Google Scholar
• Maillard-Salin DG, Becourt P, Couarraze G. A study of the adhesive-skin interface: correlation between adhesion and passage of a drug. Int J Pharm 2000;200:121-6
   PubMed Web of Science ®Google Scholar
• Bouchard P, De Cicco-Nardone F, Spielmann D, Garcea N. Bleeding profile and endometrial safety of continuous combined regimens 1 mg 17beta-estradiol/trimegestone versus 1 or 2 mg 17beta-estradiol/norethisterone acetate in postmenopausal women. Gynecol Endocrinol 2005;21:142-8
   PubMed Web of Science ®Google Scholar
• Koninckx PR, Spielmann D. A comparative 2-year study of the effects of sequential regimens of 1 mg 17beta-estradiol and trimegestone with a regimen containing estradiol valerate and norethisterone on the bleeding profile and endometrial safety in postmenopausal women. Gynecol Endocrinol 2005;21:82-9
   PubMed Web of Science ®Google Scholar
• Al-Azzawi F, Wahab M, Sami S, Randomized trial of effects of estradiol in combination with either norethisterone acetate or trimegestone on lipids and lipoproteins in postmenopausal women. Climacteric 2004;7:292-300
   PubMed Web of Science ®Google Scholar
• Warming L, Ravn P, Spielman D, Trimegestone in a low-dose, continuous-combined hormone therapy regimen prevents bone loss in osteopenic postmenopausal women. Menopause 2004;11:337-42
   PubMed Web of Science ®Google Scholar
• Chabbert-Buffet N, Ouzounian S, Kairis AP, Bouchard P. Contraceptive applications of progesterone receptor modulators. Eur J Contracept Reprod Health Care 2008;13:222-30
   PubMed Web of Science ®Google Scholar
• Brenner RM, Slayden OD, Nath A, Intrauterine administration of CDB-2914 (Ulipristal) suppresses the endometrium of rhesus macaques. Contraception 81:336-42
   PubMed Web of Science ®Google Scholar
• Stratton P, Levens ED, Hartog B, Endometrial effects of a single early luteal dose of the selective progesterone receptor modulator CDB-2914. Fertil Steril 2010;93:2035-41
   PubMed Web of Science ®Google Scholar
• Snow SE, Melillo SN, Jarvis CI. Ulipristal acetate for emergency contraception. Ann Pharmacother 2011;45:780-6
   PubMed Web of Science ®Google Scholar
• Nieman LK, Blocker W, Nansel T, Efficacy and tolerability of CDB-2914 treatment for symptomatic uterine fibroids: a randomized, double-blind, placebo-controlled, phase IIb study. Fertil Steril 2011;95:767-72; e761-762
   PubMed Web of Science ®Google Scholar
• DeManno D, Elger W, Garg R, Asoprisnil (J867): a selective progesterone receptor modulator for gynecological therapy. Steroids 2003;68:1019-32
   PubMed Web of Science ®Google Scholar
• Chwalisz K, Perez MC, Demanno D, Selective progesterone receptor modulator development and use in the treatment of leiomyomata and endometriosis. Endocr Rev 2005;26:423-38
   PubMed Web of Science ®Google Scholar
• Wilkens J, Chwalisz K, Han C, Effects of the selective progesterone receptor modulator asoprisnil on uterine artery blood flow, ovarian activity, and clinical symptoms in patients with uterine leiomyomata scheduled for hysterectomy. J Clin Endocrinol Metab 2008;93:4664-71
   PubMed Web of Science ®Google Scholar
• Safety of Treatment of Uterine Fibroids With Asoprisnil. Vol. 2008. Available from: http://clinicaltrials.gov/archive/NCT00156208, 2005
   Google Scholar
• Chwalisz K, Mattia-Goldberg K, Lee M, Treatment of endometriosis with the novel selective progesterone receptor modulator (SPRM) asoprisnil. Fertil Steril 2004;82:S83
   Web of Science ®Google Scholar
• Pasqualini JR. Progestins and breast cancer. Gynecol Endocrinol 2007;23(Suppl 1):32-41
   PubMedGoogle Scholar